mRNA Vaccines Market
授權報價
| Single User | $4,799 USD |
| Multi User | $7,999 USD |
| Enterprise / Global Site Licence | $17,999 USD |
完整報告名稱與涵蓋範圍
mRNA Vaccines Market by Target Indication (RSV Infection, Metastatic / R / R Head and Neck Cancer, Influenza, Norovirus Acute Gastroenteritis, and Mononucleosis) and Geographical Regions (North America, Europe, and Asia-Pacific) - Trends and Forecast Till 2035
報告摘要
mRNA VACCINES MARKET: OVERVIEW
As per Roots Analysis, the global mRNA vaccines market (for non-COVID applications) is estimated to grow from USD 9 million in the current year to USD 7,047 million by 2035, at an impressive CAGR of 109%, during the forecast period, till 2035.
mRNA Vaccines Market: Growth and Trends
mRNA vaccines represent a paradigm shift in preventive medicine. These vaccines rely on messenger ribonucleic acid (mRNA) to instruct host cells to manufacture a specific antigenic protein and, in turn, elicit a targeted immune response. Unlike conventional vaccine platforms that depend on live attenuated organisms, inactivated pathogens or recombinant proteins, the mRNA platform allows rapid design, scalable cell-free manufacturing and quick adaptability to emerging pathogens and antigenic drift. These significant features came to global prominence during the COVID-19 pandemic and are now being leveraged across a much broader set of indications.
The market is increasingly moving beyond its pandemic-driven origins toward a diversified mRNA vaccines opportunity, underpinned by expanding clinical pipelines and near-term commercialization prospects. Respiratory syncytial virus (RSV) remains a key area of focus, with multiple mRNA-based candidates progressing to address a significant unmet need among older adults and high-risk pediatric populations. Development activity is also intensifying across other respiratory and viral indications, including influenza and cytomegalovirus, reflecting the versatility of the mRNA modality across infectious disease prevention. Presently, over 100 mRNA-based candidates are presently being investigated for oncology-related indications alone, underscoring the platform's expansion well beyond its original scope. For instance, BioNTech has published its data on cancer vaccines that are currently in Phase II testing. These specialized therapies utilize patient-specific tumor sequencing to construct customized mRNA sequences matching an individual's unique neoantigens, aiming for a projected market launch window towards the end of the decade.
This market growth momentum is being reinforced by a growing number of mid- and late-stage clinical evidence supporting the immunogenicity, safety profile and rapid antigen-updating capability of mRNA vaccines. At present, several mRNA vaccines have secured regulatory approval, while a considerably larger number of candidates are advancing through late-stage clinical evaluation. For instance, Moderna’s Spikevax® has received the approval of supplemental Biologics License Application (sBLA) from the FDA, expanding its indication to high-risk pediatric populations (ages 6 months to 11 years) and older adults. While overall demand has normalized in the post-pandemic period, sustained investment in non-COVID vaccine development, manufacturing optimization and enabling delivery technologies is expected to support long-term market growth during the forecast period.
Growth Drivers: Factors Fueling Expansion of the Global mRNA Vaccines Market
Market expansion is being driven by the inherent speed and adaptability of the mRNA platform, which allows vaccine sequences to be designed and modified far more quickly than is possible with conventional approaches. These essential characteristics aid in resolving antigenic drift and emerging pathogens. Further, this has been complemented by steady advances in lipid nanoparticle delivery systems and large-scale, cell-free manufacturing capabilities, which have improved vaccine stability, production efficiency and commercial viability, while easing prior bottlenecks in global-scale distribution. Furthermore, the applications of the mRNA modality are broadening well beyond infectious disease prevention into oncology, rare diseases and personalized medicine, supported by encouraging early clinical results. Meanwhile, an emerging shift towards next-generation RNA platforms, including self-amplifying, circular and trans-amplifying RNA systems, is expected to further extend the durability and reach of the underlying technology, collectively positioning the mRNA vaccines market for sustained growth.
Market Challenges: Critical Barriers Hindering Progress
Despite this progressive outlook, the market continues to witness several challenges that impede overall growth. Demand for COVID-19 mRNA vaccines has normalized below pandemic-era levels, and the sector must now build a durable commercial base around non-COVID indications where reimbursement pathways, physician familiarity and public confidence are comparatively less established. Cold-chain storage and distribution requirements, though improving, continue to limit accessibility in cost-sensitive and infrastructure-constrained markets, while manufacturing capacity remains concentrated among a small number of established players, creating potential supply-side bottlenecks as pipeline candidates approach commercialization.
Moreover, regulatory pathways for novel, non-pandemic mRNA indications are still maturing in several geographies, extending development timelines relative to more established modalities. Additionally, as the number of mRNA-based candidates in active development rises across overlapping indications, such as influenza and RSV, competitive intensity and pricing pressure are likely to increase, requiring differentiated efficacy, dosing convenience or combination-vaccine strategies for developers to sustain commercial advantage.
mRNA Vaccines Market: Key Insights
The report delves into the current state of the mRNA vaccines market and identifies potential growth opportunities within the industry. Some key findings include:
• Presently, seven mRNA vaccines have secured regulatory approval and are commercially available. Moreover, a considerably larger pool of candidates is progressing through mid- and late-stage clinical trials across infectious disease and oncology indications.
• Over 100 mRNA-based candidates are currently being investigated for cancer-related indications, reflecting the platform's expansion well beyond its infectious disease origins.
• Close to 70% of ongoing clinical trials evaluating mRNA vaccines are being managed or funded by industry players, with Moderna emerging as the most active sponsor, followed by BioNTech and Sanofi; over half of the registered trials have already been completed.
• Over 1,060 patents related to mRNA vaccine technologies have been filed or granted worldwide, with filing activity accelerating sharply in the years following the COVID-19 pandemic as developers move to protect intellectual property spanning both infectious diseases and oncology applications.
• Partnership activity in this domain is intensifying. For instance, Moderna's February 2026 collaboration with the Mexican government to build a local mRNA ecosystem, spanning respiratory vaccine supply and technology transfer for domestic production.
• Among big pharma players actively partnering with smaller, specialized mRNA developers to build out their capabilities, Pfizer leads, followed by Sanofi, which has meaningfully expanded its mRNA-focused portfolio through such collaborations.
• In April 2026, Moderna's combination influenza and COVID-19 mRNA vaccine (mRNA-1083) received European Commission authorization, marking the first approved dual respiratory mRNA vaccine globally; separately, its seasonal influenza candidate (mFlusiva) is under active FDA review following data showing superior efficacy versus standard flu shots in adults aged 50-64.
• Given the breadth of the clinical pipeline, rising research and development investment and continued diversification into oncology and next-generation RNA platforms, the mRNA vaccines market is well positioned for sustained, high-growth expansion through the forecast period.
mRNA Vaccines Market
The market sizing and opportunity analysis has been segmented across the following parameters:
By Target Indication
• RSV Infection
• Metastatic / R/R Head and Neck Cancer
• Influenza
• Norovirus Acute Gastroenteritis
• Mononucleosis
By Geographical Regions
• North America
• US
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• China
• Japan
• South Korea
• Australia
• Middle East and North Africa
• Saudi Arabia
• UAE
• Latin America
• Brazil
• Argentina
mRNA Vaccines Market: Key Segments
Influenza is Poised to Emerge as the Leading Target Indication
Based on market analysis, the influenza segment is projected to capture the majority of overall market share by 2035. This growth is driven by mRNA’s ability to overcome major limitations of traditional flu vaccines. Influenza viruses evolve quickly, requiring frequent reformulation of conventional vaccines. mRNA technology enables much faster updates, allowing manufacturers to adjust the vaccine closer to flu season for a better strain match and improved effectiveness.
Moreover, influenza also offers a recurring, high-volume annual demand cycle that aligns closely with mRNA's scalable, cell-free manufacturing model, allowing the same production infrastructure to be reused each season with only sequence-level modifications, improving operating leverage and margin potential for manufacturers.
North America Holds the Highest Share
According to our projections, North America is expected to maintain its dominance as the largest and fastest-growing regional market for mRNA vaccines through 2035. This dominance is due to the region's early and concentrated investment in mRNA platform development. Recently, Moderna and Pfizer in collaboration with BioNTech established proprietary mRNA design, lipid nanoparticle delivery and large-scale manufacturing capabilities well ahead of the COVID-19 pandemic.
Additionally, substantial government risk-sharing support, most notably Operation Warp Speed, sped up clinical trials and regulatory approvals for mRNA vaccines. The FDA’s efficient and well-defined approval processes continue to facilitate faster market entry. A dominant intellectual property position in mRNA synthesis, modification and delivery technologies further reinforces high entry barriers for competitors in the region.
Europe and Asia-Pacific Offer Long-Term Opportunity
Beyond North America, Europe is expected to remain a significant contributor to global revenues, supported by the region's expanding biotech ecosystem, coordinated public health procurement and recent regulatory milestones such as the European Commission's authorization of Moderna's combination influenza-COVID-19 vaccine.
Further, Asia-Pacific’s mRNA vaccines market, while smaller in absolute terms, is expected to see growth momentum over the forecast period. This growth is likely to be driven by the growing domestic manufacturing initiatives across China and South Korea, rising government interest in pandemic-preparedness infrastructure, and an expanding base of local mRNA technology developers.
Example Players in mRNA Vaccines Market
• Arcturus Therapeutics
• BioNTech
• CureVac
• Ethris
• Gennova Biopharmaceuticals
• Immorna
• Innovac Therapeutics
• Kernal Biologics
• Moderna
• Providence Therapeutics
• Recode Therapeutics
• Rejuvenation Technologies
• RNACure
• RNAimmune
• Strand Therapeutics
• Suzhou Abogen Biosciences
• Turn Biotechnologies
• Walvax
Expert Interview and Industry Insights
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:
• Business Development Manager, Mid-sized Organization, Australia
• Senior Director, Business Development, Large Organization, Belgium
• Team Leader, Large Organization, South Korea
In addition, the report features transcripts of third-party discussions with the following individuals:
• Director of Advanced Drug Delivery, Mid-sized Organization, UK
• Deputy Director, Mid-sized Organization, US
• Co-Founder and Chief Executive Officer, Mid-sized Organization, Germany
• Co-Founder, Large Organization, Germany
• Chief Executive Officer, Large Organization, US
• Chief Executive Officer, Mid-sized Organization, US
• Chief Executive Officer, Large Organization, Italy
• President, Mid-sized Organization, Switzerland
• Medical Professional, Large Organization, Germany
mRNA VACCINES MARKET: RESEARCH COVERAGE
• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the mRNA vaccines market, focusing on key market segments, including, target indication and geographical regions, using a top-down forecasting approach validated against primary research inputs.
• mRNA Vaccines Landscape: A detailed assessment of the overall mRNA vaccines development landscape, featuring information on parameters such as phase of development, target indication, route of administration and type of technology / RNA platform. It also features analysis of developers based on year of establishment, company size and location of headquarters.
• Company Profiles: In-depth profiles of prominent players engaged in the mRNA vaccines industry, featuring information on their year of establishment, location of headquarters, company size, management team, portfolio and key initiatives.
• Clinical Trial Analysis: An analysis of completed and ongoing clinical trials related to mRNA vaccines, based on parameters such as trial registration year, trial phase, trial status, type of sponsor / collaborator, study design and leading industry / non-industry players.
• Patent Analysis: An analysis of patents filed / granted related to mRNA vaccine technologies, based on parameters such as type of patent, publication year, jurisdiction, CPC symbols, type of applicant and patent valuation.
• Recent Developments: A detailed analysis of recent partnerships, funding and investments, and big pharma initiatives within this industry, based on several relevant parameters.
• Porter's Five Forces Analysis: A qualitative analysis of five competitive forces in this domain, namely, threat of new entrants, bargaining power of buyers, bargaining power of suppliers, threat of substitutes, and rivalry among existing competitors.
• Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities and challenges affecting market growth.
Key Questions Answered in this Report
• Which are the leading companies in the mRNA vaccines market?
• Which region dominates the mRNA vaccines market?
• What are the key trends observed in the mRNA vaccines market?
• What factors are likely to influence the evolution of this market?
• What are the primary challenges faced by mRNA vaccine developers?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?
Reasons to Buy this Report
• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments; this information is valuable to both established market leaders and emerging entrants.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities and challenges, empowering data-driven decision-making.
• The report can aid businesses in identifying future opportunities in this sector and in understanding whether those opportunities are worth pursuing.
• The report helps in identifying customer demand by understanding the needs, preferences and behavior of the target audience, in order to tailor products or services effectively.
• The report equips new entrants with requisite information regarding this market to help them build successful business strategies.
• The report allows for more effective communication with the audience and in building strong business relations.
Additional Benefits
• Complementary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older
目錄 Table of Contents
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations in the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russia-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Chapter Overview
6.2. mRNA Vaccines
6.2.1. Advantages of mRNA Vaccines
6.2.2. Key Applications of mRNA Vaccines
6.3. mRNA Vaccines
6.3.1. Advantages of mRNA Vaccines
6.3.2. Key Applications of mRNA Vaccines
6.4. mRNA Delivery Routes
6.5. mRNA Delivery Strategies
6.6. Key Challenges Associated with mRNA Vaccines
6.7. Future Perspectives
7. MARKET LANDSCAPE
7.1. Chapter Overview
7.2. mRNA Vaccines: Overall Market Landscape
7.2.1. Analysis by Status of Development
7.2.2. Analysis by Type of Drug Candidate
7.2.3. Analysis by Type of Program
7.2.4. Analysis by Type of Delivery System
7.2.5. Analysis by Type of Molecule Encoded
7.2.6. Analysis by Route of Administration
7.2.7. Analysis by Therapeutic Area
7.3. mRNA Vaccines: Developer Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Most Active Developers: Analysis by Number of Drugs Developed
8. PRODUCT COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. mRNA Vaccines: Product Competitiveness Analysis
8.4.1. mRNA Vaccines Developed by Players based in North America
8.4.2. mRNA Vaccines Developed by Players based in Europe
8.4.3. mRNA Vaccines Developed by Players based in Asia-Pacific and Rest of the World
9. COMPANY PROFILES: mRNA VACCINE DEVELOPERS BASED IN NORTH AMERICA
9.1. Chapter Overview
9.2. Leading Developers in mRNA Vaccines Market based in North America
9.2.1. Arcturus Therapeutics
9.2.1.1. Company Overview
9.2.1.2. Financial Information
9.2.1.3. mRNA Vaccines Portfolio
9.2.1.4. Recent Developments and Future Outlook
9.2.2. Immorna
9.2.2.1. Company Overview
9.2.2.2. mRNA Vaccines Portfolio
9.2.2.3. Recent Developments and Future Outlook
9.2.3. Moderna
9.2.3.1. Company Overview
9.2.3.2. Financial Information
9.2.3.3. mRNA Vaccines Portfolio
9.2.3.4. Recent Developments and Future Outlook
9.2.4. Providence Therapeutics
9.2.4.1. Company Overview
9.2.4.2. Financial Information
9.2.4.3. mRNA Vaccines Portfolio
9.2.4.4. Recent Developments and Future Outlook
9.2.5. Innovac Therapeutics
9.2.5.1. Company Overview
9.2.5.2. mRNA Vaccines Portfolio
9.2.5.3. Recent Developments and Future Outlook
9.2.6. Kernal Biologics
9.2.6.1. Company Overview
9.2.6.2. Financial Information
9.2.6.3. mRNA Vaccines Portfolio
9.2.6.4. Recent Developments and Future Outlook
9.2.7. Recode Therapeutics
9.2.7.1. Company Overview
9.2.7.2. Financial Information
9.2.7.3. mRNA Vaccines Portfolio
9.2.7.4. Recent Developments and Future Outlook
9.2.8. Rejuvenation Technologies
9.2.8.1. Company Overview
9.2.8.2. Financial Information
9.2.8.3. mRNA Vaccines Portfolio
9.2.8.4. Recent Developments and Future Outlook
9.2.9. RNAimmune
9.2.9.1. Company Overview
9.2.9.2. Financial Information
9.2.9.3. mRNA Vaccines Portfolio
9.2.9.4. Recent Developments and Future Outlook
9.2.10. Turn Biotechnologies
9.2.10.1. Company Overview
9.2.10.2. Financial Information
9.2.10.3. mRNA Vaccines Portfolio
9.2.10.4. Recent Developments and Future Outlook
9.2.11. Strand Therapeutics
9.2.11.1. Company Overview
9.2.11.2. Financial Information
9.2.11.3. mRNA Vaccines Portfolio
9.2.11.4. Recent Developments and Future Outlook
10. COMPANY PROFILES: mRNA VACCINE DEVELOPERS BASED IN EUROPE
10.1. Chapter Overview
10.2. Leading Developers in mRNA Vaccines Market based in North America
10.2.1. BioNTech
10.2.1.1. Company Overview
10.2.1.2. Financial Information
10.2.1.3. mRNA Vaccines Portfolio
10.2.1.4. Recent Developments and Future Outlook
10.2.2. CureVac
10.2.2.1. Company Overview
10.2.2.2. Financial Information
10.2.2.3. mRNA Vaccines Portfolio
10.2.2.4. Recent Developments and Future Outlook
10.2.3. Ethris
10.2.3.1. Company Overview
10.2.3.2. mRNA Vaccines Portfolio
10.2.3.3. Recent Developments and Future Outlook
11. COMPANY PROFILES: mRNA VACCINE DEVELOPERS BASED IN ASIA-PACIFIC
11.1. Chapter Overview
11.2. Leading Developers in mRNA Vaccines Market based in North America
11.2.1. Suzhou Abogen Biosciences
11.2.1.1. Company Overview
11.2.1.2. mRNA Vaccines Portfolio
11.2.1.3. Recent Developments and Future Outlook
11.2.2. Gennova Biopharmaceuticals
11.2.2.1. Company Overview
11.2.2.2. Financial Information
11.2.2.3. mRNA Vaccines Portfolio
11.2.2.4. Recent Developments and Future Outlook
11.2.3. RNACure
11.2.3.1. Company Overview
11.2.3.2. mRNA Vaccines Portfolio
11.2.3.3. Recent Developments and Future Outlook
11.2.4. Walvax
11.2.4.1. Company Overview
11.2.4.2. Financial Information
11.2.4.3. mRNA Vaccines Portfolio
11.2.4.4. Recent Developments and Future Outlook
12. BIG PHARMA INITIATIVES
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. mRNA Vaccines Market: Big Player Initiatives
12.3.1. Analysis by Year of Initiative
12.3.2. Analysis by Type of Initiative
12.3.3. Analysis by Year and Type of Initiative
12.3.4. Analysis by Type of Partnership
12.3.5. Analysis by Type of Expansion
12.3.6. Analysis by Year of Initiative and Company
12.3.7. Big Pharma Players: Analysis by Number of Initiatives
12.4. Benchmarking Analysis: Big Pharma Players
12.4.1. Spider Web Analysis: Bayer
12.4.2. Spider Web Analysis: Pfizer
12.4.3. Spider Web Analysis: Sanofi
12.5. Concluding Remarks
13. START-UP HEALTH INDEXING
13.1. Chapter Overview
13.2. Start-ups focused on mRNA Vaccines
13.3. Benchmarking of Start-ups
13.4. Startup-Health Indexing
13.4.1. Analysis by Location of Headquarters
13.4.2. Analysis by Company Strength
13.4.3. Analysis by Pipeline Maturity
13.4.4. Analysis by Pipeline Strength
13.4.5. Analysis by Financial Support
13.4.6. Analysis by Investor Strength
13.4.7. Analysis by Partnership Activity
13.4.8. Start-ups Health Indexing: Roots Analysis Perspective
14. CLINICAL TRIAL ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. mRNA Vaccines: Clinical Trial Analysis
14.3.1. Analysis by Trial Registration Year
14.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year
14.3.3. Analysis by Trial Phase
14.3.4. Analysis of Number of Patients Enrolled by Trial Phase
14.3.5. Analysis by Trial Status
14.3.6. Analysis by Trial Registration Year and Trial Status
14.3.7. Analysis by Patient Gender
14.3.8. Analysis by Study Design
14.3.8.1. Analysis by Type of Allocation
14.3.8.2. Analysis by Type of Intervention Model
14.3.8.3. Analysis by Type of Masking
14.3.8.4. Analysis by Trial Purpose
14.3.9. Analysis by Type of Sponsor / Collaborator
14.3.10. Analysis by Geography
14.3.10.1. Analysis of Clinical Trials by Geography
14.3.10.2. Analysis of Clinical Trials by Geography and Trial Status
14.3.10.3. Analysis of Patients Enrolled by Geography and Trial Status
15. PARTNERSHIPS AND COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models
15.3. mRNA Vaccines Market: Partnerships and Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.3. Analysis by Year and Type of Partnership
15.3.4. Analysis by Therapeutic Area
15.3.5. Most Active Players: Analysis by Number of Partnerships
15.3.6. Analysis by Geography
15.3.6.1. Intercontinental and Intracontinental Agreements
15.3.6.2. Local and International Agreements
16. FUNDING AND INVESTMENTS
16.1. Chapter Overview
16.2. Funding Models
16.3. mRNA Vaccines Market: Funding and Investment Analysis
16.3.1. Analysis by Year of Funding
16.3.1.1. Cumulative Year-wise Trend of Funding Instances
16.3.1.2. Cumulative Year-wise Trend of Amount Invested
16.3.2. Analysis by Type of Funding
16.3.2.1. Analysis of Funding Instances
16.3.2.2. Analysis of Amount Invested
16.3.3. Analysis by Year and Type of Funding
16.3.4. Analysis by Amount Raised by Year and Type of Funding
16.3.5. Analysis by Therapeutic Area
16.3.6. Most Active Players: Analysis by Number of Funding Instances
16.3.7. Most Active Players: Analysis by Amount Raised
16.3.8. Analysis by Geography
16.3.9. Most Active Players: Analysis by Number of Funding Instances
16.3.10. Most Active Players: Analysis by Amount Invested
16.4. Summary of Funding and Investments
17. PATENT ANALYSIS
17.1. Chapter Overview
17.2. Scope and Methodology
17.3. mRNA Vaccines: Patent Analysis
17.3.1. Analysis by Type of Patent
17.3.2. Analysis by Patent Publication Year
17.3.3. Analysis by Type of Patent and Publication Year
17.3.4. Analysis by Patent Application Year
17.3.5. Analysis by Patent Jurisdiction
17.3.6. Analysis by CPC Symbols
17.3.7. Analysis by Type of Applicant
17.3.8. Leading Industry Players: Analysis by Number of Patents
17.3.9. Leading Non-Industry Players: Analysis by Number of Patents
17.3.10. Leading Inventors: Analysis by Number of Patents
17.4. Patent Benchmarking Analysis
17.4.1. Analysis of Patent Characteristics
17.5. Patent Valuation
17.6. Leading Patents by Number of Citations
18. FDA APPROVAL STRATEGIES
18.1. Chapter Overview
18.2. Methodology
18.3. Key Parameters
18.4. General Reasons for Failure of Trials Focused on mRNA Vaccines
18.5. Benchmarking Analysis: Distribution of Key Strategies by mRNA Vaccines
19 OUTSOURCING: GO / NO-GO FRAMEWORK
19.1. Chapter Overview
19.2. Outsourcing: Go / No-Go Framework
19.3. mRNA Vaccines Outsourcing: Go / No-Go Framework
19.3.1. Key Parameters and Assumptions
19.3.2. Methodology
19.3.3. Results and Interpretations
19.3.3.1. Outsourcing: Go / No-Go Framework for Small Companies
19.3.3.2. Outsourcing: Go / No-Go Framework for Mid-Sized Companies
19.3.3.3. Outsourcing: Go / No-Go Framework for Large Companies
20. MARKET IMPACT ANALYSIS
20.1. Chapter Overview
20.2. Market Drivers
20.3. Market Restraints
20.4. Market Opportunities
20.5. Market Challenges
20.6. Conclusion
21. GLOBAL mRNA VACCINES MARKET
21.1. Chapter Overview
21.2. Assumptions and Methodology
21.3. Global mRNA Vaccines Market, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
21.3.1. Scenario Analysis
21.3.1.1. Conservative Scenario
21.3.1.2. Optimistic Scenario
21.4. Key Market Segmentations
22. mRNA VACCINES MARKET, BY TARGET INDICATION
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. mRNA Vaccines Market: Distribution by Target Indication
22.3.1. mRNA Vaccines Market for RSV Infection, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
22.3.2. mRNA Vaccines Market for Metastatic / R/ R Head and Neck Cancer, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
22.3.3. mRNA Vaccines Market for Influenza, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
22.3.4. mRNA Vaccines Market for Norovirus Acute Gastroenteritis, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
22.3.5. mRNA Vaccines Market for Mononucleosis, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
22.4. Data Triangulation and Validation
23. mRNA VACCINES MARKET, BY GEOGRAPHICAL REGIONS
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. mRNA Vaccines Market: Distribution by Geographical Regions
23.3.1. mRNA Vaccines Market in North America, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.1.1. mRNA Vaccines Market in the US, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.1.2. mRNA Vaccines Market in Canada, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.2. mRNA Vaccines Market in Europe, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.2.1. mRNA Vaccines Market in Germany, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.2.2. mRNA Vaccines Market in the France, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.2.3. mRNA Vaccines Market in Italy, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.2.4. mRNA Vaccines Market in UK, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.2.5. mRNA Vaccines Market in Spain, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.2.6. mRNA Vaccines Market in Rest of Europe, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.3. mRNA Vaccines Market in Aisa-Pacific, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.3.1. mRNA Vaccines Market in China, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.3.2. mRNA Vaccines Market in Japan, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.3.3. mRNA Vaccines Market in Australia, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.3.4. mRNA Vaccines Market in South Korea, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
23.3.4. Penetration Growth (P-G) Matrix
23.3.5. Market Movement Analysis
23.4. Data Triangulation and Validation
24. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA
24.1. mRNA Vaccines Market in North America: Distribution by Target Indication
24.1.1. mRNA Vaccines Market in North America for RSV Infection, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
24.1.2. mRNA Vaccines Market in North America for Metastatic / R/ R Head and Neck Cancer, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
24.1.3. mRNA Vaccines Market in North America for Influenza, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
24.1.4. mRNA Vaccines Market in North America for Norovirus Acute Gastroenteritis, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
24.1.5. mRNA Vaccines Market in North America for Mononucleosis, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
25. MARKET OPPORTUNITY ANALYSIS: EUROPE
25.1. mRNA Vaccines Market in Europe: Distribution by Target Indication
25.1.1. mRNA Vaccines Market in Europe for RSV Infection, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
25.1.2. mRNA Vaccines Market in Europe for Metastatic / R/ R Head and Neck Cancer, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
25.1.3. mRNA Vaccines Market in Europe for Influenza, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
25.1.4. mRNA Vaccines Market in Europe for Norovirus Acute Gastroenteritis, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
25.1.5. mRNA Vaccines Market in Europe for Mononucleosis, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
26. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC
26.1. mRNA Vaccines Market in Asia-Pacific: Distribution by Target Indication
26.1.1. mRNA Vaccines Market in Asia-Pacific for RSV Infection, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
26.1.2. mRNA Vaccines Market in Asia-Pacific for Metastatic / R/ R Head and Neck Cancer, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
26.1.3. mRNA Vaccines Market in Asia-Pacific for Influenza, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
26.1.4. mRNA Vaccines Market in Asia-Pacific for Norovirus Acute Gastroenteritis, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
26.1.5. mRNA Vaccines Market in Asia-Pacific for Mononucleosis, Historical Trends (Since 2024) and Forecasted Estimates (Till 2035)
27. CONCLUDING REMARKS
28. EXECUTIVE INSIGHTS
28.1. Chapter Overview
28.2. Company A
28.2.1. Company Snapshot
28.2.2. Interview Transcript: Business Development Manager
28.3. Company B
28.3.1. Company Snapshot
28.3.2. Interview Transcript: Senior Director, Business Development
28.4. Company C
28.4.1. Company Snapshot
28.4.2. Interview Transcript: Team Leader
28.5. Company D
28.5.1. Company Snapshot
28.5.2. Interview Transcript: Director of Advanced Drug Delivery
28.6. Company E
28.6.1. Company Snapshot
28.6.2. Interview Transcript: Deputy Director
28.7. Company F
28.7.1. Company Snapshot
28.7.2. Interview Transcript: Co-founder and Chief Executive Officer
28.8. Company G
28.8.1. Company Snapshot
28.8.2. Interview Transcript: Co-founder
28.9. Company H
28.9.1. Company Snapshot
28.9.2. Interview Transcript: Chief Executive Officer
28.10. Company I
28.10.1. Company Snapshot
28.10.2. Interview Transcript: Chief Executive Officer
28.11. Company J
28.11.1. Company Snapshot
28.11.2. Interview Transcript: Chief Executive Officer
28.12. Company K
28.12.1. Company Snapshot
28.12.2. Interview Transcript: Chief Executive Officer
28.13. Company L
28.13.1. Company Snapshot
28.13.2. Interview Transcript: President
28.14. Company M
28.14.1. Company Snapshot
28.14.2. Interview Transcript: Medical Professional
29. APPENDIX 1: TABULATED DATA
30. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Roots Analysis 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們